US FDA guidance explains how to display proprietary and established drug names in promotional material
This article was originally published in SRA
The US Food and Drug Administration has issued final guidance for prescription drug manufacturers clarifying how they may display the proprietary and established names of drug products in promotional materials, including advertisements disseminated via social media websites1,2.
You may also be interested in...
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.